Search

Author/Creator Dellinger, Andrew

1. A phase I study of ABT‐510 plus bevacizumab in advanced solid tumors. (21st March 2013)

Authors:
Uronis, Hope E.; Cushman, Stephanie M.; Bendell, Johanna C.; Blobe, Gerard C.; Morse, Michael A.; Nixon, Andrew B.; Dellinger, Andrew; Starr, Mark D.; Li, Haiyan; Meadows, Kellen; Gockerman, Jon; Pang, Herbert; Hurwitz, Herbert I.
Journal:
Cancer medicine
Issue:
Volume 2:Number 3(2013:Jun.)
Page Start:
316
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Issue 2 (13th December 2013)

Authors:
Moylan, Cynthia A.; Pang, Herbert; Dellinger, Andrew; Suzuki, Ayako; Garrett, Melanie E.; Guy, Cynthia D.; Murphy, Susan K.; Ashley‐Koch, Allison E.; Choi, Steve S.; Michelotti, Gregory A.; Hampton, Daniel D.; Chen, Yuping; Tillmann, Hans L.; Hauser, Michael A.; Abdelmalek, Manal F.; Diehl, Anna Mae
Journal:
Hepatology
Issue:
Volume 59:Issue 2(2014:Feb.)
Page Start:
471
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Modulation of circulating protein biomarkers following TRC105 (anti‐endoglin antibody) treatment in patients with advanced cancer. (14th February 2014)

Authors:
Liu, Yingmiao; Starr, Mark D.; Brady, John C.; Dellinger, Andrew; Pang, Herbert; Adams, Bonne; Theuer, Charles P.; Lee, Nam Y.; Hurwitz, Herbert I.; Nixon, Andrew B.
Journal:
Cancer medicine
Issue:
Volume 3:Number 3(2014:Jun.)
Page Start:
580
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗